TRK-950 - Toray
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 9, 2026 - P1/2 | N=49 | Recruiting | Sponsor: Toray Industries, Inc | Trial completion date: Dec 2027 ➔ Mar 2028 | Trial primary completion date: Dec 2027 ➔ Mar 2028 
Trial completion date • Trial primary completion date • Oncology • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT05423262
 
Oct 9, 2026
 
Prev Next